PROK 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• increase in research costs of $0.6 million related to ongoing mechanism of action studies of rilparencel; and

• increase in professional fees of approximately $0.4 million related to the use of consultants as we begin to prepare for regulatory filings.

• decreases in cash-based compensation of approximately $0.6 million related to reductions in severance amounts paid for terminated employees; and

• decreases in professional fees and other operating costs of approximately $0.4 million driven by ongoing initiatives including the Domestication and Restructuring transactions in 2025.

• The following table summarizes our results of operations for the six months ended June 30, 2026 and 2025 (in thousands):

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• increase in compensation costs of approximately $1.2 million due to the hiring of additional personnel; offset by

• decrease in clinical study costs of $1.6 million related to clinical trials that have been completed or terminated.

• decreases in professional fees and other operating costs of approximately $1.4 million driven by ongoing initiatives including the Domestication and Restructuring transactions in 2025; and

• decreases in cash-based compensation of approximately $0.5 million related to reductions in severance amounts paid for terminated employees.

• Since our inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. From our inception thro…

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.